Content area
Full Text
A 7-year-old boy developed cushingoid face and oral moniliasis following treatment with budesonide for proteinlosing enteropathy. The boy was administered oral budesonide 9mg daily for protein-losing enteropathy secondary to restrictive cardiomyopathy. Due to cushingoid face and oral moniliasis, his budesonide dose was reduced to 6 mg/day with resolution of the side effects [duration of treatment to reaction onset not stated]. Budesonide was withdrawn at the 3rd treatment month when heart transplantation was performed. On post-operative day 13, budesonide was re-initiated due to reduced serum albumin values, and later withdrawn.